Amid all the posters, plenaries, and presentations of the nation’s biggest neurology conference, one story stood out: Spinal muscular atrophy, once an untreatable condition, has become the staging ground for one of the drug industry’s most intense competitions.
This year’s American Academy of Neurology meeting offered plenty of answers about SMA treatments from Novartis (NVS), Roche (RHHBY), and Biogen (BIIB) — but left enough questions to stir debate over just which therapy will lead the SMA market in years to come.
Here’s your guide to what we learned — and didn’t learn — about the future of treating SMA.
